Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes

Journal of Autoimmunity

Volumn 71, Issue , 2016, Pages 44-50

  Buckner, Jane H ^a   Nepom, Gerald T ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CD4 T cell; Genetic susceptibility; Immunomodulation; Type 1 diabetes

Indexed keywords

ALEFACEPT; THYMOCYTE ANTIBODY; AUTOANTIGEN; HLA ANTIGEN CLASS 2;

CD4+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EFFECTOR CELL; FUNCTIONAL DISEASE; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TARGET CELL; ADAPTIVE IMMUNITY; ANIMAL; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PANCREAS ISLET; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ADAPTIVE IMMUNITY; ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; ISLETS OF LANGERHANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84959275546     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.02.009     Document Type: Review

References (94)

1. Atkinson M.A., Maclaren N.K. Islet cell autoantigens in insulin-dependent diabetes. J. Clin. Invest. 1993, 92:1608-1616.
2. Nepom G.T. Glutamic acid decarboxylase and other autoantigens in IDDM. Curr. Opin. Immunol. 1995, 7:825-830.
3. Yang J., Danke N.A., Berger D., Reichstetter S., Reijonen H., Greenbaum C., et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J. Immunol. 2006, 176:2781-2789.
4. Roep B.O., Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb. Perspect. Med. 2012, 2:a007781.
5. Gottlieb P.A., Delong T., Baker R.L., Fitzgerald-Miller L., Wagner R., Cook G., et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J. Autoimmun. 2014, 50:38-41.
6. Oling V., Marttila J., Ilonen J., Kwok W.W., Nepom G., Knip M., et al. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J. Autoimmun. 2005, 25:235-243.
7. Oling V., Reijonen H., Simell O., Knip M., Ilonen J. Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes. Cell Immunol. 2012, 273:133-139.
8. Yang J., James E.A., Sanda S., Greenbaum C., Kwok W.W. CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitorin. Immunology 2013, 138:269-279.
9. Chow I.T., Yang J., Gates T.J., James E.A., Mai D.T., Greenbaum C., et al. Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PloS one 2014, 9:e112882.
10. Reijonen H., Mallone R., Heninger A.K., Laughlin E.M., Kochik S.A., Falk B., et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes 2004, 53:1987-1994.
11. Eugster A., Lindner A., Catani M., Heninger A.K., Dahl A., Klemroth S., et al. High diversity in the TCR repertoire of GAD65 autoantigen-specific human CD4+ T cells. J. Immunol. 2015, 194:2531-2538.
12. Mallone R., Kochik S.A., Laughlin E.M., Gersuk V.H., Reijonen H., Kwok W.W., et al. Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes 2004, 53:971-977.
13. Danke N.A., Yang J., Greenbaum C., Kwok W.W. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J. Autoimmun. 2005, 25:303-311.
14. Monti P., Scirpoli M., Rigamonti A., Mayr A., Jaeger A., Bonfanti R., et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J. Immunol. 2007, 179:5785-5792.
15. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17414-17419.
16. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., et al. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 2010, 185:3814-3818.
17. Shao S., He F., Yang Y., Yuan G., Zhang M., Yu X. Th17 cells in type 1 diabetes. Cell Immunol. 2012, 280:16-21.
18. Chujo D., Foucat E., Nguyen T.S., Chaussabel D., Banchereau J., Ueno H. ZnT8-Specific CD4+ T cells display distinct cytokine expression profiles between type 1 diabetes patients and healthy adults. PloS one 2013, 8:e55595.
19. Arif S., Leete P., Nguyen V., Marks K., Nor N.M., Estorninho M., et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014, 63:3835-3845.
20. Xu X., Zheng S., Yang F., Shi Y., Gu Y., Chen H., et al. Increased Th22 cells are independently associated with Th17 cells in type 1 diabetes. Endocrine 2014, 46:90-98.
21. Ferreira R.C., Simons H.Z., Thompson W.S., Cutler A.J., Dopico X.C., Smyth D.J., et al. IL-21 production by CD4(+) effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia 2015, 58:781-790.
22. Ryba-Stanislawowska M., Werner P., Brandt A., Mysliwiec M., Mysliwska J. Th9 and Th22 immune response in young patients with type 1 diabetes. Immunol. Res. 2015.
23. Walker L.S., von Herrath M. CD4 T cell differentiation in type 1 diabetes. Clin. Exp. Immunol. 2016, 183:16-29.
24. Nepom G.T. Conversations with GAD. J. Auto. Immun. 2003, 20:195-198.
25. Mannering S.I., Harrison L.C., Williamson N.A., Morris J.S., Thearle D.J., Jensen K.P., et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 2005, 202:1191-1197.
26. McGinty J.W., Chow I.T., Greenbaum C., Odegard J., Kwok W.W., James E.A. Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes 2014, 63:3033-3040.
27. van Lummel M., Duinkerken G., van Veelen P.A., de Ru A., Cordfunke R., Zaldumbide A., et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 2014, 63:237-247.
28. Yang J., Chow I.T., Sosinowski T., Torres-Chinn N., Greenbaum C.J., James E.A., et al. Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:14840-14845.
29. Nakayama M., McDaniel K., Fitzgerald-Miller L., Kiekhaefer C., Snell-Bergeon J.K., Davidson H.W., et al. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:4429-4434.
30. Morgan N.G., Leete P., Foulis A.K., Richardson S.J. Islet inflammation in human type 1 diabetes mellitus. IUBMB life 2014, 66:723-734.
31. Pugliese A., Vendrame F., Reijonen H., Atkinson M.A., Campbell-Thompson M., Burke G.W. New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation. Curr. diabetes Rep. 2014, 14:530.
32. Velthuis J.H., Unger W.W., van der Slik A.R., Duinkerken G., Engelse M., Schaapherder A.F., et al. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia 2009, 52:494-503.
33. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
34. Burke G.W., Vendrame F., Pileggi A., Ciancio G., Reijonen H., Pugliese A. Recurrence of autoimmunity following pancreas transplantation. Curr. Diab. Rep. 2011, 11:413-419.
35. Pathiraja V., Kuehlich J.P., Campbell P.D., Krishnamurthy B., Loudovaris T., Coates P.T., et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes. Diabetes 2015, 64:172-182.
36. Vendrame F., Pileggi A., Laughlin E., Allende G., Martin-Pagola A., Molano R.D., et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010, 59:947-957.
37. Chujo D., Foucat E., Takita M., Itoh T., Sugimoto K., Shimoda M., et al. Emergence of a broad repertoire of GAD65-specific T-cells in type 1 diabetes patients with graft dysfunction after allogeneic islet transplantation. Cell Transplant. 2012, 21:2783-2795.
38. Petersen L.D., Duinkerken G., Bruining G.J., van Lier R.A., de Vries R.R., Roep B.O. Increased numbers of in vivo activated T cells in patients with recent onset insulin-dependent diabetes mellitus. J. Autoimmun. 1996, 9:731-737.
39. Peakman M., Mahalingam M., Leslie R.D., Vergani D. Co-expression of CD45RA (naive) and CD45R0 (memory) T-cell markers. Lancet 1994, 343:424.
40. Hedman M., Faresjo M., Axelsson S., Ludvigsson J., Casas R. Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children. Clin. Exp. Immunol. 2008, 153:360-368.
41. Bollyky J.B., Long S.A., Fitch M., Bollyky P.L., Rieck M., Rogers R., et al. Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes. Clin. Exp. Immunol. 2013, 172:363-374.
42. Bian M.L., Haigh O., Munster D., Harris M., Cotterill A., Miles J.J., et al. Reactivated CD4+Tm cells of T1D patients and siblings display an exaggerated effector phenotype with heightened sensitivity to activation-induced cell death. Diabetes 2015, 64:2161-2171.
43. Han D., Leyva C.A., Matheson D., Mineo D., Messinger S., Blomberg B.B., et al. Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clin. Immunol. 2011, 139:290-301.
44. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., et al. IL-17 immunity in human type 1 diabetes. J. Immunol. 2010, 185:1959-1967.
45. Reinert-Hartwall L., Honkanen J., Salo H.M., Nieminen J.K., Luopajarvi K., Harkonen T., et al. Th1/Th17 plasticity is a marker of advanced beta cell autoimmunity and impaired glucose tolerance in humans. J. Immunol. 2015, 194:68-75.
46. Xu X., Shi Y., Cai Y., Zhang Q., Yang F., Chen H., et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PloS one 2013, 8:e79858.
47. Kenefeck R., Wang C.J., Kapadi T., Wardzinski L., Attridge K., Clough L.E., et al. Follicular helper T cell signature in type 1 diabetes. J. Clin. Invest. 2015, 125:292-303.
48. Tangye S.G. Advances in IL-21 biology - enhancing our understanding of human disease. Curr. Opin. Immunol. 2015, 34:107-115.
49. Barrett J.C., Clayton D.G., Concannon P., Akolkar B., Cooper J.D., Erlich H.A., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 2009.
50. Durinovic-Bello I., Wu R.P., Gersuk V.H., Sanda S., Shilling H.G., Nepom G.T. Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun. 2010, 11:188-193.
51. Ferreira R.C., Freitag D.F., Cutler A.J., Howson J.M., Rainbow D.B., Smyth D.J., et al. Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases. PLoSGenet 2013, 9:e1003444.
52. Rawlings D.J., Dai X., Buckner J.H. The Role of the PTPN22 Risk Variant in the Development of Autoimmunity: Finding Common Ground Between Mouse and Man. J. Immunol. 2015, 194:2977-2984.
53. Dai X., James R.G., Habib T., Singh S., Jackson S., Khim S., et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 2013, 123:2024-2036.
54. Zikherman J., Hermiston M., Steiner D., Hasegawa K., Chan A., Weiss A. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J. Immunol. 2009, 182:4093-4106.
55. Rieck M., Arechiga A., Onengut-Gumuscu S., Greenbaum C., Concannon P., Buckner J.H. Genetic Variation in PTPN22 Corresponds to Altered Function of T and B Lymphocytes. J. Immunol. 2007, 179:4704-4710.
56. Vang T., Landskron J., Viken M.K., Oberprieler N., Torgersen K.M., Mustelin T., et al. The autoimmune-predisposing variant of lymphoid tyrosine phosphatase favors T helper 1 responses. Hum. Immunol. 2013, 74:574-585.
57. Long S.A., Cerosaletti K., Wan J.Y., Ho J.C., Tatum M., Wei S., et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun. 2011, 12:116-125.
58. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
59. Patel D.D., Kuchroo V.K. Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions. Immunity 2015, 43:1040-1051.
60. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., et al. Interleukin-2 signaling via STAT5 constraints T helper 17 cell generation. Immunity 2007, 26:371-381.
61. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Zhu J., Grainger J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 2011, 12:247-254.
62. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010, 33:153-165.
63. Araki M., Chung D., Liu S., Rainbow D.B., Chamberlain G., Garner V., et al. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J. Immunol. 2009, 183:5146-5157.
64. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
65. de Jong V.M., Zaldumbide A., van der Slik A.R., Laban S., Koeleman B.P., Roep B.O. Variation in the CTLA4 3'UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes. Genes Immun. 2016, 17:75-78.
66. Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J. allergy Clin. Immunol. 2007, 120(744-50):51-52.
67. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 2008, 181:7350-7355.
68. Lawson J.M., Tremble J., Dayan C., Beyan H., Leslie R.D., Peakman M., et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 2008, 154:353-359.
69. Venigalla R.K., Tretter T., Krienke S., Max R., Eckstein V., Blank N., et al. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 2008, 58:2120-2130.
70. Vargas-Rojas M.I., Crispin J.C., Richaud-Patin Y., Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008, 17:289-294.
71. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 2009, 183:3170-3176.
72. Schneider A., Long S.A., Cerosaletti K., Ni C.T., Samuels P., Kita M., et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci. Transl. Med. 2013, 5:170ra15.
73. Trinschek B., Luessi F., Haas J., Wildemann B., Zipp F., Wiendl H., et al. Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoSONE 2013, 8:e77634.
74. Gregori S., Giarratana N., Smiroldo S., Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 2003, 171:4040-4047.
75. You S., Belghith M., Cobbold S., Alyanakian M.A., Gouarin C., Barriot S., et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005, 54:1415-1422.
76. D'Alise A.M., Auyeung V., Feuerer M., Nishio J., Fontenot J., Benoist C., et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. ProcNatlAcadSciUSA 2008, 105:19857-19862.
77. Clough L.E., Wang C.J., Schmidt E.M., Booth G., Hou T.Z., Ryan G.A., et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J. Immunol. 2008, 180:5393-5401.
78. Yang J., Brook M.O., Carvalho-Gaspar M., Zhang J., Ramon H.E., Sayegh M.H., et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19954-19959.
79. Ruprecht C.R., Gattorno M., Ferlito F., Gregorio A., Martini A., Lanzavecchia A., et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. 2005, 201:1793-1803.
80. Ben Ahmed M., Belhadj H.N., Moes N., Buyse S., Abdeladhim M., Louzir H., et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2009, 182:6763-6770.
81. Peluso I., Fantini M.C., Fina D., Caruso R., Boirivant M., MacDonald T.T., et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 2007, 178:732-739.
82. Goodman W.A., Young A.B., McCormick T.S., Cooper K.D., Levine A.D. Stat3 Phosphorylation Mediates Resistance of Primary Human T Cells to Regulatory T Cell Suppression. J. Immunol. 2011.
83. Bradshaw E.M., Raddassi K., Elyaman W., Orban T., Gottlieb P.A., Kent S.C., et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 2009, 183:4432-4439.
84. Gitelman S.E., Gottlieb P.A., Rigby M.R., Felner E.I., Willi S.M., Fisher L.K., et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. lancet Diabetes & Endocrinol. 2013, 1:306-316.
85. Rigby M.R., Harris K.M., Pinckney A., DiMeglio L.A., Rendell M.S., Felner E.I., et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Invest. 2015, 125:3285-3296.
86. Rigby M.R., DiMeglio L.A., Rendell M.S., Felner E.I., Dostou J., Gitelman S.E., et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (TIDAL study): 12 month resutls of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013, 1:284-294.
87. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
88. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1692-1698.
89. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
90. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
91. Daifotis A.G., Koenig S., Chatenoud L., Herold K.C. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin. Immunol. 2013, 149:268-278.
92. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
93. Tooley J.E., Vudattu N., Choi J., Cotsapas C., Devine L., Raddassi K., et al. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur. J. Immunol. 2016, 46:230-241.
94. Orban T., Beam C.A., Xu P., Moore K., Jiang Q., Deng J., et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 2014, 63:3449-3457.